Coya Therapeutics to Participate in BTIG Virtual Biotechnology Conference

Coya Therapeutics, a clinical-stage biotech company, will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company is developing biologics to enhance regulatory T cell function, which aims to target systemic inflammation and neuroinflammation. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company's investigational product candidate pipeline leverages multiple therapeutic modalities to restore Treg function.

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, has announced its participation in the BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025. The company's management team will be available for one-on-one meetings with investors during the event, providing an opportunity for investors to discuss the company's pipeline and future prospects.

The BTIG Virtual Biotechnology Conference is a platform for biotechnology companies to engage with investors and showcase their innovative products and technologies. Coya Therapeutics' participation in this event underscores the company's commitment to advancing its therapeutic pipeline and seeking investment opportunities to support its growth.

Coya Therapeutics is headquartered in Houston, Texas, and focuses on developing proprietary treatments aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. The company's investigational product candidate pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, leveraging multiple therapeutic modalities to target systemic inflammation and neuroinflammation.

The company's forward-looking statements highlight the potential risks and uncertainties associated with the development and commercialization of its product candidates. These risks include the impact of COVID-19, the success of clinical trials, the ability to obtain regulatory approval, and market acceptance of the company's products.

For more information about the BTIG Virtual Biotechnology Conference or to schedule a one-on-one meeting with Coya Therapeutics' management team, investors should contact their BTIG representative. For further details about Coya Therapeutics and its product pipeline, visit [Coya Therapeutics' website](https://www.coyatherapeutics.com).

References:
1. [Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference](https://www.businesswire.com/news/home/20250722618751/en/Coya-Therapeutics-to-Participate-in-the-BTIG-Virtual-Biotechnology-Conference-July-29-30-2025)